QCOR Questcor Pharmaceutical Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QCOR Questcor Pharmaceutical

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Savant	10/17/2013 6:12:56 AM
	of 107

Questcor Pharmaceuticals Inc. (QCOR) increased its quarterly dividend 20%, pointing to greater cash flow. The five-cent boost to 30 cents a share also marks a 50% increase year over year and will cost the company about an extra $3 million a quarter. The dividend will be paid on or about Oct. 30. The pharmaceutical company's results have been boosted by an increase in sales of its H.P. Acthar Gel for the treatment of infantile spasms, rheumatoid arthritis and other ailments. "Our second dividend increase this year reflects our strong financial performance to date, driven by increasing usage of Acthar among physicians to treat patients with serious, difficult to treat medical conditions," Chief Executive Don M. Bailey said. He added the company had $278 million in cash and investments at Oct. 4. In July, Questcor reported its second-quarter profit grew 67% on increased adoption of its primary drug, Acthar. Shares of Questcor, which is slated to report third-quarter results Oct. 29, were up 6.7% in recent trading to $58.24 and have more than doubled this year.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next